National Cancer Database analysis of radiation therapy consolidation modality and dose for inoperable endometrial cancer
Brachytherapy · 2024
DOI: 10.1016/j.brachy.2024.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von Alexander Lukez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA, 19111, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Brachytherapy, Databases, Factual, Radiotherapy Dosage. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
OBJECTIVE: We utilized the National Cancer Database (NCDB) to evaluate trends and assess outcomes in radiation therapy (RT) boost modality and total dose among medically inoperable endometrial cancer (EC) patients with locoregional disease. METHODS: Patients with International Federation of Gynecology and Obstetrics (FIGO) stage I - IIIC2 inoperable EC treated with RT ± chemotherapy were analyzed. Practice patterns compared external beam RT (EBRT) versus high-dose-rate brachytherapy (BT) boost and total RT dose (palliative: ≤3000 cGy, definitive low dose [DLD]: 4500 - 6249 cGy, definitive high dose [DHD]: ≥6250 cGy) over time. Kaplan-Meier method evaluated overall survival (OS) and Cox proportional hazard modeling assessed variables associated with OS. RESULTS: NCDB included 1755 total cases, of which 1209 received a radiotherapy boost. From 2004 to 2019, boost modality rates differed with increasing utilization of BT consolidation and a decreasing rate of palliation. Predictors of a palliative dose were stage III disease, Black race, N2 disease, and poorly or undifferentiated grade. Multivariable analysis found BT boost was associated with lower mortality compared to EBRT (HR: 0.81, CI: 0.68-0.97; p = 0.019). Mortality rates were higher for palliation versus DHD. Additional factors associated with inferior survival were increasing age, worse Charlson-Deyo score, higher T stage, higher N stage, and moderately, poorly, or undifferentiated grade. CONCLUSIONS: Utilization of BT boost for locoregionally confined, medically inoperable EC has increased since 2004. Brachytherapy consolidation remains an effective RT modality for medically inoperable EC, associated with lower mortality compared to EBRT consolidation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA, 19111, USA.
- Fox Chase Cancer Center, Biostatistics and Bioinformatics Facility, Philadelphia, PA, 19111, USA.
- MHP, Radiation Oncology Institute, Department of Radiation Oncology, Clarkston, MI, 48346, USA.
- Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA, 19111, USA. Electronic address: jeremy.price@tuhs.temple.edu.
Förderung
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Lukez, A., Egleston, B. L., Lee, P. L., Howell, K. J., & Price, J. G. (2024). National Cancer Database analysis of radiation therapy consolidation modality and dose for inoperable endometrial cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.06.005
Vancouver
Lukez A, Egleston BL, Lee PL, Howell KJ, Price JG. National Cancer Database analysis of radiation therapy consolidation modality and dose for inoperable endometrial cancer. Brachytherapy. 2024. doi:10.1016/j.brachy.2024.06.005
BibTeX
@article{Lukez2024,
author = {Lukez, Alexander and Egleston, Brian L and Lee, Peter L and Howell, Krisha J and Price, Jeremy G},
title = {National Cancer Database analysis of radiation therapy consolidation modality and dose for inoperable endometrial cancer},
journal = {Brachytherapy},
year = {2024},
doi = {10.1016/j.brachy.2024.06.005}
}
EUVIMED